Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | DCK | P27707 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24871430 | 0.81 | MEN1 (0.51) | PDE3BPDE3APDE10AEPHX2AVPR1A | |
| SCHEMBL29947205 | 0.81 | LIPE (0.49) | — | |
| SCHEMBL14334877 | 0.80 | GRIN2D (0.47) | PDE3BPDE3APDE10AEPHX2SCN9A | |
| SCHEMBL29947136 | 0.75 | FPR2 (0.45) | DCKRET | |
| SCHEMBL29483156 | 0.74 | HRH3 (0.52) | PDE3BPDE3APDE10AEPHX2RET | |
| SCHEMBL11225815 | 0.74 | EPHX2 (0.50) | PDE3BPDE3APDE10AEPHX2AVPR1A | |
| SCHEMBL20266971 | 0.72 | AVPR1A (0.49) | EPHX2AVPR1AAVPR2KCNH2 | |
| SCHEMBL29605026 | 0.72 | AVPR1A (0.49) | EPHX2AVPR1AAVPR2KCNH2 | |
| SCHEMBL2743227 | 0.71 | PDE3B (0.50) | PDE3BPDE3APDE10AEPHX2AVPR1A | |
| SCHEMBL20412701 | 0.71 | EPHX2 (0.49) | PDE3BPDE3APDE10AEPHX2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240992-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | TRPM2, TRPM7, TRPM8 | PDE3B 2654/4885PDE3A 2719/4885PDE10A 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.